Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2019 2
2020 1
2021 2
2022 1
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Uncovering the mode of action of engineered T cells in patient cancer organoids.
Dekkers JF, Alieva M, Cleven A, Keramati F, Wezenaar AKL, van Vliet EJ, Puschhof J, Brazda P, Johanna I, Meringa AD, Rebel HG, Buchholz MB, Barrera Román M, Zeeman AL, de Blank S, Fasci D, Geurts MH, Cornel AM, Driehuis E, Millen R, Straetemans T, Nicolasen MJT, Aarts-Riemens T, Ariese HCR, Johnson HR, van Ineveld RL, Karaiskaki F, Kopper O, Bar-Ephraim YE, Kretzschmar K, Eggermont AMM, Nierkens S, Wehrens EJ, Stunnenberg HG, Clevers H, Kuball J, Sebestyen Z, Rios AC. Dekkers JF, et al. Among authors: johanna i. Nat Biotechnol. 2023 Jan;41(1):60-69. doi: 10.1038/s41587-022-01397-w. Epub 2022 Jul 25. Nat Biotechnol. 2023. PMID: 35879361 Free PMC article.
Dual targeting of cancer metabolome and stress antigens affects transcriptomic heterogeneity and efficacy of engineered T cells.
Hernández-López P, van Diest E, Brazda P, Heijhuurs S, Meringa A, Hoorens van Heyningen L, Riillo C, Schwenzel C, Zintchenko M, Johanna I, Nicolasen MJT, Cleven A, Kluiver TA, Millen R, Zheng J, Karaiskaki F, Straetemans T, Clevers H, de Bree R, Stunnenberg HG, Peng WC, Roodhart J, Minguet S, Sebestyén Z, Beringer DX, Kuball J. Hernández-López P, et al. Among authors: johanna i. Nat Immunol. 2024 Jan;25(1):88-101. doi: 10.1038/s41590-023-01665-0. Epub 2023 Nov 27. Nat Immunol. 2024. PMID: 38012415
Identification of a tumor-specific allo-HLA-restricted γδTCR.
Kierkels GJJ, Scheper W, Meringa AD, Johanna I, Beringer DX, Janssen A, Schiffler M, Aarts-Riemens T, Kramer L, Straetemans T, Heijhuurs S, Leusen JHW, San José E, Fuchs K, Griffioen M, Falkenburg JH, Bongiovanni L, de Bruin A, Vargas-Diaz D, Altelaar M, Heck AJR, Shultz LD, Ishikawa F, Nishimura MI, Sebestyén Z, Kuball J. Kierkels GJJ, et al. Among authors: johanna i. Blood Adv. 2019 Oct 8;3(19):2870-2882. doi: 10.1182/bloodadvances.2019032409. Blood Adv. 2019. PMID: 31585951 Free PMC article.
Accelerating development of engineered T cell therapies in the EU: current regulatory framework for studying multiple product versions and T2EVOLVE recommendations.
Ammar D, Schapitz I, Luu M, Hudecek M, Meyer M, Taps T, Schröder B, Ivics Z, Sanges C, Franz P, Koehl U, Negre H, Johanna I, Awigena-Cook J. Ammar D, et al. Among authors: johanna i. Front Immunol. 2023 Nov 24;14:1280826. doi: 10.3389/fimmu.2023.1280826. eCollection 2023. Front Immunol. 2023. PMID: 38077331 Free PMC article. Review.
Basics of advanced therapy medicinal product development in academic pharma and the role of a GMP simulation unit.
Johanna I, Daudeij A, Devina F, Nijenhuis C, Nuijen B, Romberg B, de Haar C, Haanen J, Dolstra H, Bremer E, Sebestyen Z, Straetemans T, Jedema I, Kuball J. Johanna I, et al. Immunooncol Technol. 2023 Oct 14;20:100411. doi: 10.1016/j.iotech.2023.100411. eCollection 2023 Dec. Immunooncol Technol. 2023. PMID: 38192616 Free PMC article. Review.
Adding Help to an HLA-A*24:02 Tumor-Reactive γδTCR Increases Tumor Control.
Johanna I, Hernández-López P, Heijhuurs S, Scheper W, Bongiovanni L, de Bruin A, Beringer DX, Oostvogels R, Straetemans T, Sebestyen Z, Kuball J. Johanna I, et al. Front Immunol. 2021 Oct 25;12:752699. doi: 10.3389/fimmu.2021.752699. eCollection 2021. Front Immunol. 2021. PMID: 34759930 Free PMC article.
Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds.
van Diest E, Hernández López P, Meringa AD, Vyborova A, Karaiskaki F, Heijhuurs S, Gumathi Bormin J, van Dooremalen S, Nicolasen MJT, Gatti LCDE, Johanna I, Straetemans T, Sebestyén Z, Beringer DX, Kuball J. van Diest E, et al. Among authors: johanna i. J Immunother Cancer. 2021 Nov;9(11):e003850. doi: 10.1136/jitc-2021-003850. J Immunother Cancer. 2021. PMID: 34815357 Free PMC article.
An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability.
van Gils MJ, van den Kerkhof TL, Ozorowski G, Cottrell CA, Sok D, Pauthner M, Pallesen J, de Val N, Yasmeen A, de Taeye SW, Schorcht A, Gumbs S, Johanna I, Saye-Francisco K, Liang CH, Landais E, Nie X, Pritchard LK, Crispin M, Kelsoe G, Wilson IA, Schuitemaker H, Klasse PJ, Moore JP, Burton DR, Ward AB, Sanders RW. van Gils MJ, et al. Among authors: johanna i. Nat Microbiol. 2016 Nov 14;2:16199. doi: 10.1038/nmicrobiol.2016.199. Nat Microbiol. 2016. PMID: 27841852 Free PMC article.
TEG011 persistence averts extramedullary tumor growth without exerting off-target toxicity against healthy tissues in a humanized HLA-A*24:02 transgenic mice.
Johanna I, Hernández-López P, Heijhuurs S, Bongiovanni L, de Bruin A, Beringer D, van Dooremalen S, Shultz LD, Ishikawa F, Sebestyen Z, Straetemans T, Kuball J. Johanna I, et al. J Leukoc Biol. 2020 Jun;107(6):1069-1079. doi: 10.1002/JLB.5MA0120-228R. Epub 2020 Feb 5. J Leukoc Biol. 2020. PMID: 32022317 Free PMC article.